Bacteria-Responsive Nanostructured Drug Delivery Systems for Targeted Antimicrobial Therapy
Abstract
Bacteria exhibit adaptive phenotypic traits that confer resistance to host defenses and antimicrobial therapies. In response to the global threat of antimicrobial resistance, bacteria-responsive nanostructured drug delivery systems have emerged as a promising alternative to conventional broad-spectrum antimicrobials. These systems release therapeutics selectively in response to bacterial presence or to their secreted enzymes, toxins, antigens, or extracellular biomarkers, enabling precise activation at infection sites while minimizing off-target effects. Bacterial components such as membrane proteins, signaling molecules, biofilm-associated glycolipids, and enzymes (e.g., lipase, hyaluronidase) serve as triggers for these smart carriers. Exopolysaccharides are also commonly targeted using nanocarriers with complementary recognition elements. Such systems are often surface-modified or loaded with antimicrobials for on-demand release. Benefits include enhanced selectivity, reduced side effects, improved biofilm penetration, higher intracellular accumulation, and potential for personalized therapy. A variety of materials-including lipid-based carriers, metal nanoparticles, polymer nanoparticles, and inorganic nanomaterials-have been engineered to release antimicrobials only in the presence of pathogenic bacteria, often offering dual therapeutic effects (e.g., anti-inflammatory). Furthermore, many platforms integrate multiple antimicrobial mechanisms, reducing the likelihood of…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.